5 Revealing Analyst Questions From Stryker's Q2 Earnings Call

Stryker’s second quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and profit expectations. Management described robust demand across its core product portfolio, particularly highlighting double-digit growth in MedSurg and Neurotechnology and solid performance in orthopedics. CEO Kevin Lobo pointed to strong U.S. momentum, driven by procedural volume growth, expanding adoption of robotic-assisted surgery, and healthy hospital capital spending. However, lingering supply chain challenges in the Medical division and ongoing tariff impacts tempered the overall narrative.

Is now the time to buy SYK? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Stryker’s Q2 Earnings Call

• Lawrence H. Biegelsen (Wells Fargo) asked about the supply issue in the Medical division and timeline for resolution. CEO Kevin Lobo explained the problem was contained and expected to persist through year-end, but stressed robust demand in unaffected segments.

• Robert Justin Marcus (JPMorgan) pressed for details on margin resilience amid tariffs and NRE dilution. CFO Preston Wells pointed to long-term pricing strategies, manufacturing efficiencies, and operational discipline as key drivers of margin consistency.

• Ryan Benjamin Zimmerman (BTIG) questioned why Stryker’s tariff impact was only modestly reduced. Wells cited shifts in U.S.-China and EU tariffs, as well as the company’s manufacturing footprint, as reasons for the smaller decrease.

• Joanne Karen Wuensch (Citibank) inquired about the new Mako Gen 4 launch and future impact. Lobo indicated strong customer feedback, noting spine and shoulder applications are in limited launch, with broader impact expected next year.

• Christopher Thomas Pasquale (Nephron Research) asked if Stryker sees a need for multiple robotic form factors. Lobo responded the current Mako system’s value comes from adding new applications, but did not rule out future portfolio expansion if market needs shift.

Catalysts in Upcoming Quarters

As we look to coming quarters, the StockStory team will closely monitor (1) the pace of regulatory approvals and international launches for key products like LIFEPAK 35 and Insignia, (2) the resolution of supply chain issues in the Medical division and their effect on volume recovery, and (3) the continued momentum in robotic installations and procedural adoption. Additionally, we will watch how Stryker’s operating discipline manages ongoing tariff and cost headwinds.

Stryker currently trades at $376.01, down from $394.22 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.